Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 41Thoracic 4Head & Neck 4Gynecologic 4Genitourinary 2Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 44Urinary Bladder Neoplasms 42Testicular Neoplasms 30Carcinoma, Transitional Cell 30Ovarian Neoplasms 28Testicular Germ Cell Tumor 16Carcinoma, Non-Small-Cell Lung 14Melanoma 11Kidney Neoplasms 11Carcinoma, Renal Cell 11Breast Neoplasms 11Wilms Tumor 10Urethral Neoplasms 10Teratoma 10Sarcoma 10Pancreatic Neoplasms 10Central Nervous System Neoplasms 10Colorectal Neoplasms 9Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Stomach Neoplasms 7Ovarian Germ Cell Cancer 7Neoplasms 7Seminoma 6Osteosarcoma 6Neuroblastoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Ureteral Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5

Interventions

pembrolizumab 6Nivolumab 3Carboplatin 2spartalizumab 1regorafenib 1obinutuzumab 1naptumomab estafenatox 1liposomal doxorubicin 1enzalutamide 1durvalumab 1atezolizumab 1aflibercept 1abiraterone 1abemaciclib 1SGN-LIV1A 1Ritonavir 1Remote Patient Monitoring 1Paclitaxel 1NEO212 1Lopinavir 1Itraconazole 1Isotretinoin 1Ipilimumab 1Interferon-alpha 1Immunohistochemistry 1IFL protocol 1House Calls 1Home Care Services 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Carboplatin × Genitourinary × Clear all
NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 1 Recruiting
1,006 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡